Paul, yuo have some misunderstending!
Gladstone cllaboration on AD is completly new, thirt, program at CNSI.
It is not a ion-channel blockers approach. This even make news more positive.
CNSI proved it success in I-C B with CERESTAT at the half of P-III trials, and with Allergan coloboration. In field, where big players break thear teeth, CNSI and BI are on the way to develop first I-C B for Stroke and TBI. Interim results for TBI are sheduled in 1-Q 1997.
Second CNSI program, Protein Growth Factors(MS, Neuropathy, Spinal cord injuries), I expect, will bring new collaborators to CNSI.
Also thay have I-C CNS 5161, which will be second collaboration with BI.
I pek few more shares after PO price-drop, because 11 PO price is low for carent CNSI position. They have been forced for(early) today announcment to strengh next year PO.
Miljenko |
